Oxford Biomedica PLC — Investor Relations & Filings
Oxford Biomedica (OXB) is a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. A pioneer in the field, the company has extensive experience in viral vectors, the enabling technology for many advanced therapies. OXB provides end-to-end services to pharmaceutical and biotechnology partners, supporting programs from preclinical development through to commercial launch. Its core expertise includes the development and GMP manufacturing of various vector types, including lentivirus, adeno-associated virus (AAV), and adenovirus. The company offers proprietary technologies like its LentiVector™ platform, the first commercially approved lentiviral system, and its inAAVate™ platform for AAV, in addition to tech-transfer capabilities.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| AGM Minutes | 2026-05-07 | English | |
| Result of AGM | 2026-05-07 | English | |
| Total Voting Rights | 2026-05-01 | English | |
| Admission to Trading | 2026-04-30 | English | |
| Admission to Trading Application | 2026-04-27 | English | |
| Launch of viral vector fast-track offering | 2026-04-13 | English |
Browse filings by year
17 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 43633533 | AGM Minutes | 2026-05-07 | English | ||
| 43197184 | Result of AGM | 2026-05-07 | English | ||
| 39399113 | Total Voting Rights | 2026-05-01 | English | ||
| 39034920 | Admission to Trading | 2026-04-30 | English | ||
| 37376856 | Admission to Trading Application | 2026-04-27 | English | ||
| 34392469 | Launch of viral vector fast-track offering | 2026-04-13 | English | ||
| 33897356 | Grant of Awards | 2026-04-08 | English | ||
| 33128279 | Total Voting Rights | 2026-04-01 | English | ||
| 33090029 | Annual financial and audit reports | 2026-03-30 | English | ||
| 33090024 | Annual financial and audit reports | 2026-03-30 | English | ||
| 33090019 | 2026 Annual General Meeting notification | 2026-03-30 | English | ||
| 33089974 | 2026 Notice of AGM | 2026-03-30 | English | ||
| 33045671 | Preliminary results for the year ended 31 Dec 2025 | 2026-03-26 | English | ||
| 32970907 | Licensing agreement with VVMF | 2026-03-18 | English | ||
| 32916724 | Admission to Trading | 2026-03-09 | English | ||
Financials
We couldn't load the financials
No data available yet
We have extracted financials for Oxford Biomedica PLC, but not for this combination of statement and period. Try a different combination.
Swipe the table to view all periods, or rotate your phone for a wider view.
| Line item | ! |
|---|---|
| Definition not yet available — coming soon. |
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
BIOLIFE SOLUTIONS INC
Manufactures biopreservation media and tools for cell and g…
|
BLFS | US | Manufacturing |
|
BioLineRx Ltd.
A clinical-stage biopharmaceutical company developing thera…
|
BLRX | IL | Manufacturing |
|
BIOMARIN PHARMACEUTICAL INC
A global biotechnology company developing therapies for rar…
|
BMRN | US | Manufacturing |
|
BioMaxima S.A.
Manufacturer and distributor of in-vitro diagnostics for cl…
|
BMX | PL | Manufacturing |
|
Biomea Fusion, Inc.
A clinical-stage biopharma developing oral drugs for diabet…
|
BMEA | US | Manufacturing |
|
BIOME AUSTRALIA LIMITED
Develops and distributes evidence-based probiotics and comp…
|
BIO | AU | Manufacturing |
|
Biome Grow Inc.
Production and distribution of cannabis products focused on…
|
BIO | CA | Manufacturing |
|
BIOMERICA INC
Develops in-vitro diagnostic and therapeutic products for c…
|
BMRA | US | Manufacturing |
|
bioMérieux
A global leader in in vitro diagnostics for clinical and in…
|
BIM | FR | Manufacturing |
|
BIOMM SA
Develops and manufactures biopharmaceuticals and biosimilar…
|
— | BR | Manufacturing |
Oxford Biomedica PLC via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/5190/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=5190 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=5190 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=5190 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 5190}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Oxford Biomedica PLC (id: 5190)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.